Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
BOSTON and ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq:IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced preliminary outcomes of the Company’s discussion with the U.S. Food and Drug Administration (FDA) on the path to approval of IkT-001Pro in blood cancers, the Company’s prodrug of the anticancer agent imatinib mesylate.
Related news for (IKT)
- Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
- Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
- inhibikase therapeutics announces closing of up to $275 million financing and advancement of ikt-001pro into a late stage clinical trial in pulmonary arterial hypertension
- inhibikase therapeutics announces pricing of $110 million private placement to advance ikt-001pro, an optimized prodrug of imatinib, into a late-stage trial in pulmonary arterial hypertension
- 24/7 Market News Snapshot 09 October, 2024 – Inhibikase Therapeutics, Inc. Common Stock (NASDAQ:IKT)